XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 1,354,549 $ 694,757
General and administrative 1,176,977 1,319,819
Sales and marketing 148,046 53,685
Total operating expenses 2,679,572 2,068,261
Operating loss (2,679,572) (2,068,261)
Other income:    
Other income, net 139,729 54,858
Total other income (139,729) (54,858)
Net loss $ (2,539,843) $ (2,013,403)
Net loss per share - Basic and diluted (in Dollars per share) $ (0.12) $ (0.1)
Weighted average common shares outstanding:    
Basic and diluted (in Shares) 20,375,092 20,142,300